These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 23133953)

  • 1. [Chemotherapy].
    Ueda T
    Nihon Rinsho; 2012 Apr; 70 Suppl 2():202-6. PubMed ID: 23133953
    [No Abstract]   [Full Text] [Related]  

  • 2. [Recent research progress of rhythmic chemotherapy in patients with hematological neoplasm].
    Yu M; Zhou F; Hou J
    Zhonghua Xue Ye Xue Za Zhi; 2011 Apr; 32(4):281-3. PubMed ID: 21569717
    [No Abstract]   [Full Text] [Related]  

  • 3. To cap or not to cap: chemotherapy dosing in obese adult hematology patients.
    Sandhu G; Mapp S; Carrington C; Hennig S
    Clin Pharmacol Ther; 2014 Apr; 95(4):356-8. PubMed ID: 24646484
    [No Abstract]   [Full Text] [Related]  

  • 4. [Combination chemotherapy and high-dose chemotherapy].
    Yamauchi T; Ueda T
    Nihon Rinsho; 2007 Jan; 65 Suppl 1():369-74. PubMed ID: 17474434
    [No Abstract]   [Full Text] [Related]  

  • 5. Bendamustine: a new therapeutic option for hematologic malignancies.
    Cheson BD
    Clin Adv Hematol Oncol; 2008 Sep; 6(9):631-3. PubMed ID: 18827785
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies.
    Ravandi F; Pigneux A; DeAngelo DJ; Raffoux E; Delaunay J; Thomas X; Kadia T; Kantarjian H; Scheuenpflug J; Zhao C; Guo W; Smith BD
    Blood Cancer J; 2015 Dec; 5(12):e375. PubMed ID: 26657199
    [No Abstract]   [Full Text] [Related]  

  • 7. [Treatment of cancer with high-dose chemotherapy and autologous stem cell transplantation].
    Geisler CH; Daugaard KG; Dickmeiss E; Ifversen M; Knudsen LM
    Ugeskr Laeger; 2003 Dec; 165(50):4846-9. PubMed ID: 14716902
    [No Abstract]   [Full Text] [Related]  

  • 8. [Future directions of antibody therapy].
    Oguro M
    Nihon Rinsho; 2007 Jan; 65 Suppl 1():629-36. PubMed ID: 17474471
    [No Abstract]   [Full Text] [Related]  

  • 9. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies.
    Berger R; Rotem-Yehudar R; Slama G; Landes S; Kneller A; Leiba M; Koren-Michowitz M; Shimoni A; Nagler A
    Clin Cancer Res; 2008 May; 14(10):3044-51. PubMed ID: 18483370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Fever in the neutropenic onco-hematologic patient: critical considerations].
    Garavelli PL
    Recenti Prog Med; 2006 May; 97(5):266. PubMed ID: 16838558
    [No Abstract]   [Full Text] [Related]  

  • 11. Health-related quality of life and symptom assessment in clinical research of patients with hematologic malignancies: where are we now and where do we go from here?
    Efficace F; Novik A; Vignetti M; Mandelli F; Cleeland CS
    Haematologica; 2007 Dec; 92(12):1596-8. PubMed ID: 18055981
    [No Abstract]   [Full Text] [Related]  

  • 12. [Antineoplastic agents and biologic response modifiers in oncologic hematology].
    Cabrera Marín JR; Briz del Blanco M
    Rev Clin Esp; 1999 Apr; 199 Suppl 1():3-13. PubMed ID: 10422445
    [No Abstract]   [Full Text] [Related]  

  • 13. [Ambulatory chemotherapy in hematology. A challenge ...].
    Montagne C; Duran B
    Soins; 1996 Sep; (608):62-8. PubMed ID: 8954491
    [No Abstract]   [Full Text] [Related]  

  • 14. Plasma leptin levels vary with the periods during chemotherapy.
    Minami R; Muta K; Ilseung C; Matsushima T; Abe Y; Nishimura J; Nawata H
    Am J Hematol; 2003 Oct; 74(2):145. PubMed ID: 14508806
    [No Abstract]   [Full Text] [Related]  

  • 15. Management of hematological malignancies in patients affected by renal failure.
    Niscola P; Vischini G; Tendas A; Scaramucci L; Giovannini M; Bondanini F; Romani C; Brunetti GA; Cartoni C; Cupelli L; Ferrannini M; Perrotti A; Del Poeta G; Palumbo R; de Fabritiis P
    Expert Rev Anticancer Ther; 2011 Mar; 11(3):415-32. PubMed ID: 21417855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The feasibility of early discharge with oral antimicrobial therapy in low risk patients with febrile neutropenia following chemotherapy for hematologic malignancies.
    Cordonnier C
    Haematologica; 2006 Feb; 91(2):150a. PubMed ID: 16461296
    [No Abstract]   [Full Text] [Related]  

  • 17. Intrathecal chemotherapy for hematologic malignancies: drugs and toxicities.
    Kwong YL; Yeung DY; Chan JC
    Ann Hematol; 2009 Mar; 88(3):193-201. PubMed ID: 19050889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arsenic derivatives as therapeutic agents for hematologic malignancies.
    Verstovsek S; Estrov Z
    Leuk Res; 2004 Sep; 28(9):901-3. PubMed ID: 15234564
    [No Abstract]   [Full Text] [Related]  

  • 19. Investigational antibody-drug conjugates for hematological malignancies.
    Polson AG; Ho WY; Ramakrishnan V
    Expert Opin Investig Drugs; 2011 Jan; 20(1):75-85. PubMed ID: 21142808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Hematologic malignancies/pediatric malignancies].
    Usui N
    Gan To Kagaku Ryoho; 2012 May; 39(5):731. PubMed ID: 22701898
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.